2018
DOI: 10.24075/brsmu.2018.026/translation
|View full text |Cite
|
Sign up to set email alerts
|

Human enteroviruses exhibit selective oncolytic activity in the model of human glioblastoma multiforme xenografts in immunodeficient mice

Abstract: Основным источником возникновения рецидивов мультиформной глиобластомы после хирургического вмешательства являются стволовые клетки, успевающие проникнуть глубоко в ткани мозга. В настоящее время актуален поиск новых подходов для борьбы с ними, в том числе с помощью онколитических вирусов. Целью работы было определение чувствительности к непатогенным энтеровирусам клеток мультиформной глиобластомы человека, поддерживаемых in vitro и в модели мышиных ксенотрансплантатов. Культуры опухолевых клеток глиобластом и… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 9 publications
(9 reference statements)
0
2
0
Order By: Relevance
“…Coxsackievirus B6 (LEV-15L strain) has been patented as an efficient treatment against HPV-negative cervical cancer (RU 2496873). Coxsackievirus A7 and B5 have been successfully used to destroy glioblastoma stem cells and reduce tumor development [ 11 , 108 ]. In order to minimize immune response after oncolytic virus administration, a novel delivery system using human dendritic cells (US2020/0352993) and NK-92 cells has been developed [ 109 ].…”
Section: Oncolytic Viruses In Clinical Trialsmentioning
confidence: 99%
“…Coxsackievirus B6 (LEV-15L strain) has been patented as an efficient treatment against HPV-negative cervical cancer (RU 2496873). Coxsackievirus A7 and B5 have been successfully used to destroy glioblastoma stem cells and reduce tumor development [ 11 , 108 ]. In order to minimize immune response after oncolytic virus administration, a novel delivery system using human dendritic cells (US2020/0352993) and NK-92 cells has been developed [ 109 ].…”
Section: Oncolytic Viruses In Clinical Trialsmentioning
confidence: 99%
“…A different approach consists of selecting those viruses that are known to have good biosafety profiles and are easy to work with. In this respect, the vaccinia virus and as well as coxsackie virus have attracted a considerable attention [19,25,26,[28][29][30]. Combining these two practical themes, several Russian groups have focused their efforts on adenoviruses as arguably the most promising candidates for virotherapy [31,32].…”
Section: Diversity Of Viruses As the Basis For The Development Of New Ovsmentioning
confidence: 99%